Page last updated: 2024-12-08

cellotetraose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cellotetraose: RN given refers to (beta-D)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cellotetraose : A glucotetrose comprised of four D-glucose residues connected by beta(1->4) linkages. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439626
CHEBI ID62974
MeSH IDM0139423

Synonyms (11)

Synonym
C02013
cellotetraose
38819-01-1
cellotetraose, >=85% (hplc)
beta-d-glucopyranosyl-(1->4)-beta-d-glucoopyranosyl-(1->4)-beta-d-glucoopyranosyl-(1->4)-d-glucoopyranose
d-cellotetraose
beta-d-glcp-(1->4)-beta-d-glcp-(1->4)-beta-d-glcp-(1->4)-d-glcp
CHEBI:62974
3-amino-3-cyclohexyl-propionicacidamide
mfcd00079079
LUEWUZLMQUOBSB-YQGOCCRESA-N
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glucotetraoseAny tetrasaccharide composed of 4 glucose moieties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (2.82)18.7374
1990's11 (15.49)18.2507
2000's21 (29.58)29.6817
2010's35 (49.30)24.3611
2020's2 (2.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other72 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]